osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['osimertinib', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
#asco22 dr. presents an update on chrysalis-2: amivantamab + lazertinib in patients with #egfr mutant nsclc post progression on osimertinib and chemotherapy. amivantamab is a bispecific antibody targeting egfr and #met and lazertinib is a 3g egfr tki. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him